1Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma [J]. BJU Int, 2004, 93 (3): 297 - 302.
2Na X, Wu G, Ryan CK, et al. Overpro- duction of vascular endothelial growth factor related to yon Hippel - Lindau tumor suppressor gene mutations and hypoxiainducible factor - 1 a expression in renal cell careinomas[ J ]. Int J Urol, 2003, 170 (2Pt I): 588-592.
3Srinivasan R, Armstrong AJ, Dahut W, et al. Anti - aslgiogenic therapy in renal cell cancer [J]. BJU lnt, 2007, 99 (5 Pt B) : 1296- 1300.
47Aaang XH, Yanmshita M, Uetsuki H, et al. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothdial growth factor and matrix metalloproteinzses [ J ]. J Urol, 2002, 9 ( 9 ) : 509 - 514.
5Ljungberg BJ, Jacobin J, Rudolfsson SH, et al. Different vascular endothelial growth factor (VEGF), VEGF - receptor 1 and - 2 mRNA expression profiles between clear cell and papillary renal cell carcinoma [J]. BJU lnt, 2006, 98 (3): 661-667.
6Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognosis factor in renal cell carcinoma [J]. J Urol, 2000, 163: 343-347.
7Klatte T, Bohm M, Nelius T, et al. E- valuation of peri - operative peripheral and renal venous levels of pro - and anti - angiogenic factors and their relevance in patients with renal cell carcinoma [ J ]. BJU Int, 2007, 100 (1): 209-214.
8Baldewijns MM, Thijssen VL, Van den Eynden GG, et al. High - grade clear cell renal cell carcinoma has a higher angiogenic activity than lowgrade renal cell carcinoma based on histomorphological quantification and qRTPCR mRNA expression profile [J]. BrJ Cancer, 2007, 96 (12): 1888 - 1895.
9MacLennan GT, Bostwick DG . Microvessel density in renal cell carcinoma: lack of prognostic significance [ J ]. Urology, 1995, 46 (1): 27-30.
10Raica M, Cimpean AM, Anghel A, et al. Immtmohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microves.sel density in renal cell carcinoma [ J]. Neoplasma, 2007, 54 (4) : 278 - 284.
二级参考文献6
1Jinzaki M, Tanimoto A, Mukai M, et al. Double-phase helical CT of small renal parenchymal meoplasms: Correlation with pathological findings and tumor angiogensis[J]. J Computer Assisted Tomography,2000,24(6):835-42.
2Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognosic factor in renal cell carcinoma[J]. J Urol,2000,163(1):343-7.
3Kedar D, Baker CH, Killion JJ, et al. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice[J]. Clin Cancer Res,2002,8(11):3592-600.
4Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma[J]. J Natl Cancer Inst,1992,84(24):1875-87.
5Chang SG, Jeon SH, Lee SJ, et al. Clinical significance of urinary vascular endothelial growth factor and microvessel density in patient with renal cell cacinoma[J]. Urology,2001,58(6):904-8.
6Hemmerlein B, Kulgler A. Ozisik R, et al. Vascular endothelial growth factor expression, angiogensis, and necrosis in renal cell carcinomas[J]. Virchows Arch,2001,439(5):545-52.
6Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases[J].I-Ium Pathol,2007, 38(10) : 1489-1495.
7Raskopf E, Vogt A, Sauerbruch T, et al. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo[J].J Hepatol,2008,49(6) : 977-984.
8魏恩.坎贝尔-沃尔什泌尿外科学[M].9版,北京:北京大学出版社,2009:1668-1669.
9Liou LS, Shi T, Duan ZH, et al. Microarray gene expression profi- ling and analysis in renal cell carcinoma[ J]. BMC Uro1,2004 ,4 (1) :9.
10Wood C, Srivastava P. An adjuvant autologous therapeutic vaccine (HSPPC -96, vitespen)versus observation alone for patients at high risk of recto'fence after nephrectomy for renal cell carcino- ma : a muhicentre, open - label, randomised phase IH trial [ J ]. Lancet ,2008,372 ( 9633 ) : 145 - 154.
